Evidence map›Paper›PMID 42676389›Full record

ArticleFrontiers in oncology2026

High dose IFN-α2b as post operative adjuvant therapy for acral melanoma: a multi-center real-world cohort study of 171 Chinese patients.

Kaidi Yang, Shiji Lan, Yan Wang, Jin Wu, Xin Cai, Kui Jiang, Zhen Guo, Mei Xiang, Hongfeng Zhou, Jiwei Li and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Kaidi Yang *Cancer Center, The First Hospital of Jilin University, Changchun, China.
Shiji Lan *Cancer Center, The First Hospital of Jilin University, Changchun, China.
Yan WangMedical Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China.
Jin WuDepartment of head and neck genitourinary medicine, Harbin Medical University Cancer Hospital, Harbin, China.
Xin CaiThe First Affiliated Hospital of Dalian Medical University, Dalian, China.
Kui JiangDepartment of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Zhen GuoCancer Center, The First Hospital of Jilin University, Changchun, China.
Mei XiangMedical Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China.
Hongfeng ZhouDepartment of head and neck genitourinary medicine, Harbin Medical University Cancer Hospital, Harbin, China.
Jiwei LiThe First Affiliated Hospital of Dalian Medical University, Dalian, China.
Fang LiuDepartment of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Jianping GuiCancer Center, The First Hospital of Jilin University, Changchun, China.
Yuhuan MaoMedical Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China.
Hongxue MengDepartment of head and neck genitourinary medicine, Harbin Medical University Cancer Hospital, Harbin, China.
Xiang JiThe First Affiliated Hospital of Dalian Medical University, Dalian, China.
Janan PangCancer Center, The First Hospital of Jilin University, Changchun, China.
Xinxin YangDepartment of head and neck genitourinary medicine, Harbin Medical University Cancer Hospital, Harbin, China.
Lu FengThe First Affiliated Hospital of Dalian Medical University, Dalian, China.
Weizhen ZhangMedical Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China.
Di WuCancer Center, The First Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study aimed to investigate recurrence patterns and survival outcomes in Chinese patients with AM who received postoperative adjuvant High-dose interferon (HD-IFN), and to assess how treatment duration and the interval between surgery and therapy initiation relate to recurrence and survival. Methods: A multi-center, retrospective cohort study involving 171 patients with AM who received postoperative adjuvant HD-IFN therapy between January 2012 and March 2025 was conducted at five melanoma diagnostic and treatment centers across China. Results: The median follow-up duration was 75.7 months. Median recurrence-free survival (RFS) and overall survival (OS) were 37.5 and 93.7 months, respectively. Stratified by recurrence risk, patients in the low-risk, high-risk, and very high-risk groups had median RFS of 64.1, 31.6, and 13.8 months ( Conclusion: Results show that full-course HD-IFN treatment is statistically associated with improved survival in high-risk and very high-risk subgroups, whereas the timing of HD-IFN initiation within 3 months after surgery makes no significant difference to prognosis.

Indexed as

acral melanomaadjuvant therapyclinical and pathological characteristicshigh-dose interferon-alpha-2bimmunotherapy

Identifiers

PMID42676389
PMCPMC13526564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.